Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Therapeutic Innovation & Regulatory Science
|
August 5, 2025
Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials
Philip He, Haijun Ma, Chengxing Cindy Lu, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
|
July 22, 2010
[The identification of the "Beijing family" strain of clinical isolated Mycobacterium tuberculosis in the south region of Xinjiang]
Chang-dong Wu, Shu Wen, Li-gu Mi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 22, 2017
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Carlo Genova, Mark A Socinski, Rebecca R Hozak, et al.
The Oncologist
|
June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 17, 2020
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Roy S Herbst, Hendrik Tobias Arkenau, Johanna Bendell, et al.
Journal of Global Oncology
|
August 8, 2018
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
Chia-Jui Yen, Kei Muro, Tae-Won Kim, et al.
Cancers
|
October 20, 2020
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
Ian Chau, Nicolas Penel, Andres O Soriano, et al.
The Lancet. Oncology
|
July 15, 2019
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Therapeutic Innovation & Regulatory Science
|
August 5, 2025
Ensuring Quality and Interpretability of Progression Free Survival and Overall Survival in Oncology Clinical Trials
Philip He, Haijun Ma, Chengxing Cindy Lu, et al.
Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese Journal of Tuberculosis and Respiratory Diseases
|
July 22, 2010
[The identification of the "Beijing family" strain of clinical isolated Mycobacterium tuberculosis in the south region of Xinjiang]
Chang-dong Wu, Shu Wen, Li-gu Mi, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 22, 2017
EGFR Gene Copy Number by FISH May Predict Outcome of Necitumumab in Squamous Lung Carcinomas: Analysis from the SQUIRE Study
Carlo Genova, Mark A Socinski, Rebecca R Hozak, et al.
The Oncologist
|
June 2, 2018
Ramucirumab Plus Pembrolizumab in Patients with Previously Treated Advanced or Metastatic Biliary Tract Cancer: Nonrandomized, Open-Label, Phase I Trial (JVDF)
Hendrik-Tobias Arkenau, Juan Martin-Liberal, Emiliano Calvo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 23, 2020
Ramucirumab and durvalumab for previously treated, advanced non-small-cell lung cancer, gastric/gastro-oesophageal junction adenocarcinoma, or hepatocellular carcinoma: An open-label, phase Ia/b study (JVDJ)
Yung-Jue Bang, Talia Golan, Laetitia Dahan, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 17, 2020
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Roy S Herbst, Hendrik Tobias Arkenau, Johanna Bendell, et al.
Journal of Global Oncology
|
August 8, 2018
Ramucirumab Safety in East Asian Patients: A Meta-Analysis of Six Global, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trials
Chia-Jui Yen, Kei Muro, Tae-Won Kim, et al.
Cancers
|
October 20, 2020
Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial
Ian Chau, Nicolas Penel, Andres O Soriano, et al.
The Lancet. Oncology
|
July 15, 2019
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, et al.
Page
of 2